基于HIS数据的抑郁障碍患者亚型及证候分布特征分析

发布时间：2018-04-28 04:38

本文选题：抑郁障碍 + 电子医疗数据　；参考：《中国中医基础医学杂志》2014年09期

【摘要】：目的:了解抑郁障碍患者的西医亚型及中医证候分布特征。方法:全国19家三甲综合医院诊断抑郁障碍的住院患者信息,运用频数统计进行分析。结果:抑郁障碍患者常见中医证候为肝郁气滞占32.91%,肝郁痰阻占12.66,脾两虚占11.39%;抑郁症占73.17%,器质性抑郁障碍占5.64%,双相情感障碍抑郁发作比例占2.21%,抑郁状态比例占18.97%。器质性抑郁障碍男性比例占10.31%,女性比例占3.62%,双相抑郁男性占3.54%,女性比例占3.98%。自2008年至2010年,器质性抑郁障碍的比例从11.19%逐步降至5.82%、4.30%,双相抑郁障碍的比例从1.40%升至2.04%、3.61%;治愈率抑郁症为22.23%,器质性抑郁障碍0.99%;治愈率为7.69%,抑郁状态治愈率为7.81%。结论:抑郁障碍患者肝郁气滞为最常见中医证候,亚型分布中抑郁症比例最高;双相情感障碍抑郁发作比例逐年增高;器质性抑郁障碍男性多于女性,随着年龄增加患者比例渐增高,随年代推移逐渐降低。
[Abstract]:Objective: to investigate the subtypes of western medicine and the distribution of TCM syndromes in patients with depression. Methods: the information of hospitalized patients with depressive disorder in 19 hospitals of China was analyzed with frequency statistics. Results: the common TCM syndromes in patients with depression were liver depression qi stagnation 32.91, liver stagnation phlegm obstruction 12.66, spleen deficiency 11.39%, depression 73.1717, organic depression 5.64, bipolar affective disorder 2.21 and depression 18.97. The proportion of men with organic depression was 10.31, the proportion of women was 3.62, the proportion of bipolar depression was 3.54 and the proportion of women was 3.98. From 2008 to 2010, the proportion of organic depression decreased from 11.19% to 5.820.30, the proportion of bipolar depression increased from 1.40% to 2.040.61; the cure rate of depression was 22.23%, organic depression 0.9999; the cure rate was 7.69; the cure rate of depression was 7.81. Conclusion: liver depression and qi stagnation are the most common TCM syndromes in patients with depressive disorder, the proportion of depression is the highest in subtype distribution, the proportion of bipolar affective disorder is increasing year by year, the male with organic depression is more than female, With the increase of age, the proportion of patients gradually increased, gradually decreased with the passage of time.
【作者单位】：中国中医科学院中医临床基础医学研究所;北京回龙观医院;中国人民解放军海军总医院;中国人民大学;
【基金】：国家“重大新药创制”科技重大专项(2009ZX09502-030)
【分类号】：R749.4

【相似文献】